An error occurred retrieving publication content to display, please try again.
Page not found (404)
Sorry - the page you requested could not be found.
Please choose a page from the navigation or try a website search above to find the information you need.
Toolkit
Study found lapatinib combined with an aromatase inhibitor (AI) and trastuzumab combined with an AI to be clinically more effective than AI monotherapy for the first-line treatment of patients who have hormone receptor-positive/human epidermal growth factor 2-positive metastatic breast cancer. However, neither of these treatments are cost-effective compared with AIs alone.
1 Liverpool Reviews and Implementation Group (LRiG), University of Liverpool, Liverpool, UK
2 Department of Public Health Medicine, University of Liverpool, Liverpool, UK
3 North West Medicines Information Centre, Liverpool, UK
4 The Christie NHS Foundation Trust, Manchester, UK
5 Clatterbridge Centre for Oncology NHS Foundation Trust, Wirral, UK
* Corresponding author Email: r.dickson@liv.ac.uk
Funding: {{metadata.Funding}}
{{metadata.Journal}} Volume: {{metadata.Volume}}, Issue: {{metadata.Issue}}, Published in {{metadata.PublicationDate | date:'MMMM yyyy'}}
https://doi.org/{{metadata.DOI}}
Citation:{{author}}{{ (($index < metadata.AuthorsArray.length-1) && ($index <=6)) ? ', ' : '' }}{{(metadata.AuthorsArray.length <= 6) ? '.' : '' }} {{(metadata.AuthorsArray.length > 6) ? 'et al. ' : ''}}. {{metadata.JournalShortName}} {{metadata.PublicationDate | date:'yyyy'}};{{metadata.Volume}}({{metadata.Issue}})
Report Content
The full text of this issue is available as a PDF document from the Toolkit section on this page.
The full text of this issue is available as a PDF document from the Toolkit section on this page.
Responses to this report
No responses have been published.
An error has occurred in processing the XML document